BioCentury
ARTICLE | Politics, Policy & Law

BMS to seek review of CAFC’s reversal of $1.2B judgment against Gilead

Bristol Myers says decision in Yescarta case does not affect its CAR T assets

August 26, 2021 11:18 PM UTC

BMS will challenge a ruling by a federal appeals court that has overturned a $1.2 billion judgement against Gilead. The U.S. Court of Appeals for the Federal Circuit ruled that a jury erred in when it upheld a broad CAR-T patent held by Juno Therapeutics and the Sloan Kettering Institute for Cancer Research.

Bristol Myers Squibb Co. (NYSE:BMY), which said it disagrees with the CAFC’s ruling, will seek review of the decision. The company added, the “Federal Circuit’s decision does not have any impact on the development of any of BMS’s CAR-T assets.”...